Perinatal Infections - Global Strategic Business Report

The global market for Perinatal Infections was valued at US$1.6 Billion in 2025 and is projected to reach US$2.1 Billion by 2032, growing at a CAGR of 4.2% from 2025 to 2032. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Perinatal Infections Market - Key Trends & Drivers Summarized

Why Are Perinatal Infections a Critical Concern in Neonatal and Maternal Health?

Perinatal infections refer to infections acquired by the fetus or newborn either in utero, during labor and delivery, or shortly after birth. Common pathogens include Group B Streptococcus, Listeria monocytogenes, Escherichia coli, cytomegalovirus, herpes simplex virus, and rubella. These infections can lead to severe complications such as neonatal sepsis, meningitis, pneumonia, stillbirth, or long-term developmental impairments.

Early detection and timely intervention are essential for improving maternal and neonatal outcomes. However, many perinatal infections are asymptomatic or show nonspecific signs, making diagnosis challenging. Global health systems are under growing pressure to enhance prenatal screening, vaccination, and intrapartum infection control, especially in low-resource settings where infection-related mortality remains high.

How Are Screening and Prevention Strategies Evolving Globally?

Prenatal care increasingly includes routine screening for key infectious agents like HIV, hepatitis B, syphilis, and Group B strep. Polymerase chain reaction (PCR) and other molecular techniques are improving diagnostic sensitivity and turnaround time for intrauterine infections. Intrapartum antibiotic prophylaxis (IAP), particularly for Group B strep, has proven effective in reducing early-onset neonatal sepsis.

Vaccination plays a growing role in prevention. Maternal immunization against influenza, pertussis, and hepatitis B helps protect both mother and newborn. Research is advancing in maternal vaccines for respiratory syncytial virus (RSV), Group B strep, and cytomegalovirus. Point-of-care testing tools and digital maternal health platforms are helping expand access to infection management in rural and underserved areas.

Where Is the Focus of Public Health Programs and Clinical Investment Concentrated?

High-income countries have well-established protocols for managing perinatal infections, while middle- and low-income countries are scaling up prenatal testing and maternal immunization programs. Public health agencies, NGOs, and maternal-child health organizations are investing in capacity building for antenatal care, birth preparedness, and infection surveillance.

Hospitals, obstetric clinics, and neonatal intensive care units are integrating rapid diagnostic tools and antimicrobial stewardship strategies. Clinical research is focusing on improved pathogen-specific assays, therapies to manage vertical transmission, and maternal vaccines. The private sector is developing diagnostic kits, multiplex PCR panels, and infection risk scoring algorithms tailored to perinatal care settings.

Growth in the Perinatal Infections market is driven by several factors

Growth in the perinatal infections market is driven by factors such as rising awareness of infection-related neonatal mortality, expansion of prenatal screening programs, and progress in maternal immunization strategies. Global initiatives to reduce neonatal sepsis and prevent stillbirths are intensifying demand for infection control tools and obstetric diagnostics.

Advances in molecular testing technologies, increased deployment of point-of-care diagnostic solutions, and the inclusion of perinatal infection screening in universal antenatal care packages are also supporting market expansion. In addition, regulatory encouragement for maternal vaccines and investment in health infrastructure in low-income countries are contributing to wider adoption of prevention and management solutions.

Report Scope

The report analyzes the Perinatal Infections market, presented in terms of market value (US$). The analysis covers the key segments and geographic regions outlined below:

• Segments: Infection Type (Natural Infection, Cytomegalovirus Infection, Enterovirus Infection, Genital Herpes Infection, Gonorrhea Infection, Human Immunodeficiency Virus Infection, Rubella Infection, Syphilis Infection, Other Infections); Treatment (Antibiotic Treatment, Antiviral Treatment, Antiretroviral Treatment, Other Treatments); End-Use (Hospitals & Clinics End-Use, Ambulatory Surgery Centers End-Use, Other End-Uses)
• Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Natural Infection segment, which is expected to reach US$681.9 Million by 2032 with a CAGR of a 5.4%. The Cytomegalovirus Infection segment is also set to grow at 3.3% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, valued at $423.1 Million in 2025, and China, forecasted to grow at an impressive 7.5% CAGR to reach $432.7 Million by 2032. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Perinatal Infections Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Perinatal Infections Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Perinatal Infections Market expected to evolve by 2032?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2032?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2025 to 2032.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as Abbott Laboratories, Becton, Dickinson and Co., bioMérieux, Bio-Rad Laboratories, Cepheid and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the companies featured in this Perinatal Infections market report include:

• Abbott Laboratories
• Becton, Dickinson and Co.
• bioMérieux
• Bio-Rad Laboratories
• Cepheid
• Danaher Corporation
• DiaSorin S.p.A.
• EKF Diagnostics
• F. Hoffmann-La Roche Ltd
• Hologic, Inc.
• Merck & Co., Inc.
• PerkinElmer Inc.
• QIAGEN N.V.
• QuidelOrtho Corporation
• Revvity, Inc. (formerly part of PerkinElmer)
• Siemens Healthineers
• Thermo Fisher Scientific
• Trinity Biotech
• Vircell S.L.
• ZEUS Scientific, Inc.

What Sets This Report Apart From Others?

• Grounded in Domain Expert Perspectives: Incorporates perspectives emerging from domain experts across industry, enterprise and academia, adding context beyond conventional published research.
• Captures Early Market Signals: Tracks shifts emerging through expert conversations, company activity and market-relevant discussions before they are fully reflected in traditional secondary research.
• Draws From a Broad, Validated Intelligence Base: Brings together insights from conference sessions, keynotes, panel discussions, blogs, corporate disclosures, annual reports, institutional publications and other validated sources.
• Connects Signals With Strategic Market Direction: Synthesizes these perspectives to identify where the market is moving, what is driving that movement and which developments are likely to matter most for strategy.
• Provides In-Depth Company Intelligence: Extends beyond market-level analysis to examine the companies participating in and shaping the competitive environment.
• Market Share Is Examined Where It Matters: A single global market share figure rarely tells the full story. Competitive structures can vary significantly across geographies. Where analytically relevant, the report extends market share analysis into major regions with the level of detail tailored to the structure and dynamics of each market.